Stryker invests $400m in CMR Surgical - and could buy the rest
Article excerpt
Highlighted: the sentence this signal was extracted from
Multinational US medical technologies company Stryker has invested $400million in the acquisition of exclusive US commercial rights to CMR Surgical's Versius portfolio - with a further exclusive option to acquire the remaining equity at a later date. The sensational alliance means CMR Surgical's established platform and robotics expertise will align with Stryker's scale, customer relationships and commercial reach to accelerate growth of its Versius surgical robotic portfolio. The minority investment - CMR's last official valuation was for $3billion in 2021 during a $600m Series D funding round led by SoftBank and Ally Bridge - means Stryker will serve as the exclusive US sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialisation in non-US markets. The alliance comes as demand for robotic-assisted surgery - in a market which CMR entered in 2014 - continues to grow, creating an opportunity to help healthcare providers expand robotic-assisted surgery programs with a scalable and practical solution. CMR Surgical's second-generation robot, the Versius Plus, was launched in December 2025, following the launch of the original product in 2019. In the last seven years the Versius has clocked up more than 45,000 surgical procedures globally across over 30 countries. It now has established clinical experience globally...
Keep reading with a free account
The rest of this article, and every signal for Stryker, is in your free account.
